Returning as the largest and definitive ADC congress, the 17th World ADC San Diego is THE one-stop bioconjugate shop, bringing together the global ADC community for an unparalleled amalgamation of case studies, development trends and networking opportunities to forge ADC innovation into differentiated, early-line patient outcomes.

With 7 streams of end-to-end ADC content across Discovery Chemistry, Discovery Biology, Preclinical, Translational Medicine, Clinical Lessons, Process & Analytical Development, and Manufacturing & Supply, all ADC innovation will be in the spotlight for an unmissable week of data and insights to de-risk future ADC development and push ADCs into earlier line oncology treatments.

Uniting 1,300 industry senior enthusiasts from biopharma, innovative start-ups, leading service providers and academic, physician and regulator KOLs, World ADC San Diego is the place to discuss, debate and advance the future of ADC development.

Featuring 170+ senior presenters, a snapshot of the 2026 speaker faculty includes:

• Suzanne Edavettal, Vice President, Research & Head, Protein Therapeutics, Amgen
• Vinod Bulusu, Executive Director, Product Stewardship Lead, AstraZeneca
• Giorgia Vicentini, Vice President, Global Program Lead, Oncology, Bristol Myers Squibb
• Ronald Fleming, Executive Director, Clinical Development, Daiichi Sankyo
• Gail Lewis, Distinguished Scientist, Discovery Oncology, Genentech
• Min Hu, Senior Vice President, Discovery, Innovent Biologics
• Bob Lutz, Chief Scientific Officer, Iksuda Therapeutics
• Jeffrey Settleman, Chief Scientific Officer, Oncology R&D, Pfizer
• Dominik Schumacher, Chief Executive Officer, Tubulis
• Rita Nanda, Associate Professor, Medicine & Director, Breast Oncology, Section of Hematology/Oncology, University of Chicago

View the full list of speaking companies: https://ter.li/xsz013cs

If you want to stay competitive in the field, you cannot miss World ADC San Diego to de-risk future ADC development and push ADCs to earlier-line oncology treatments.